Glioblastoma remains one of the most aggressive brain cancers, with limited treatment options beyond surgery, radiation, and chemotherapy. Personalized immunotherapy represents a model shift, matching individual tumor characteristics to targeted protocols. Key Takeaways Select cancer centers offer personalized immunotherapy through clinical trials and specialized programs, with eligibility determined by thorough biomarker testing rather than universal availability Major proto